Search
Displaying 311–320 of 651 for “retinal diseases”
-
Research News
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
Research NewsKnown as ultevursen, the USH2A RNA therapy was licensed from ProQR.
-
AAVantgarde Bio’s Dual-Vector USH1B Gene Therapy Moves into Phase 1/2 Clinical Trial
Research NewsThe trial is the first ever for a dual AAV gene therapy delivered to the retina.
-
Join the Foundation Fighting Blindness for our new program, Vision Connection, an enriching and supportive gathering for the blind and low vision community.
-
Research News
Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials
-
New Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients
Research NewsThe report also concludes that vitamin E supplementation accelerates vision loss for RP patients
-
Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
Research NewsThe company is also launching modifier gene therapy clinical trials for GA and Stargardt disease
-
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
Research NewsFirst cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
-
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Research NewsKnown as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
.png)
